EPS for MusclePharm Corp (MSLP) Expected At $-0.06

November 7, 2017 - By Michael Collier

 EPS for MusclePharm Corp (MSLP) Expected At $ 0.06
Investors sentiment Infinity in 2017 Q2. Its in 2017Q1. It [12345], as 0 investors sold MusclePharm Corp shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 2.97 million shares or 6.90% more from 2.78 million shares in 2017Q1 were reported.
Wynnefield Cap Incorporated invested 0.96% of its portfolio in MusclePharm Corp (OTCMKTS:MSLP). Howard Capital Management has 10,000 shares for 0% of their portfolio.

Wall Street await MusclePharm Corp (OTCMKTS:MSLP) to release earnings on November, 8. Analysts forecast EPS of $-0.06, down exactly $0.04 or 200.00 % from 2014’s $-0.02 EPS. After posting $-0.13 EPS for the previous quarter, MusclePharm Corp’s analysts now forecast -53.85 % EPS growth. About 6,710 shares traded. MusclePharm Corp (OTCMKTS:MSLP) has 0.00% since November 7, 2016 and is . It has underperformed by 16.70% the S&P500.

MusclePharm Corporation is a performance lifestyle company. The company has market cap of $11.59 million. The Firm develops, makes, markets and distributes branded nutritional supplements. It has a 4.83 P/E ratio. The Firm offers a range of powders, capsules, tablets and gels.

More notable recent MusclePharm Corp (OTCMKTS:MSLP) news were published by: Seekingalpha.com which released: “MusclePharm up 19%, capital raise in the offing?” on September 21, 2017, also Seekingalpha.com with their article: “MusclePharm: Improving, But Still In A Tough Position” published on June 01, 2016, Seekingalpha.com published: “MusclePharm: It’s All About The Cash” on April 06, 2015. More interesting news about MusclePharm Corp (OTCMKTS:MSLP) were released by: Prnewswire.com and their article: “MusclePharm Announces Hiring Of New Chief Financial Officer” published on December 02, 2016 as well as Seekingalpha.com‘s news article titled: “MusclePharm’s Beefed-Up Turnaround Story” with publication date: January 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.